Author(s)

Kounpiélimé Sosthène Somda^1*, Abdel Karim Sermé¹, Aboubacar Coulibaly¹, Steve Léonce Zoungrana², Inès Compaoré¹, Serges Kouamou¹, Damien Ouattara², Roger Sombié¹, Alain Bougouma¹

¹Hepato-Gastroenterology Unit, Teaching Hospital Yalgado Ouédraogo, Ouagadougou, Burkina Faso.
²Gastroenterology Unit, UFR/SDS, CUP, Ouahigouya, Burkina Faso.

The treatment of chronic hepatitis B (CHB) has increased significantly in recent years. In patients affected by HBeAg-negative CHB, it is necessary to distinguish the inactive carriers (low viral DNA < 2000 IU/mL, normal ALT, histological lesions absent or minimal) who does not need treatment, and patients suffering from active CHB (DNA > 2000 IU/ml, high transaminases or fluctuating, significant fibrosis and/or necro-inflammatory activity > 1) who must be treated. The main purpose of treatment is to obtain a long-lasting viral suppression to improve the histological lesions and reduce the risk of evolution towards cirrhosis, liver failure and hepatocellular carcinoma (HCC). It about an indefinite treatment (unless HBsAg seroclearance) expensive and often inaccessible for the majority of our patients. Our study aimed to report the results of four years follow-up of HBeAg-negative patients treated by Nucleos(t)ide analogues (NAs) in Ouagadougou (Burkina Faso). It was a clinical observational study with 133 patients including 95 men; the average age was 41.2 years, completing the criteria of treatment. One hundred and twelve patients were treated by tenofovir (TDF), fourteen by lamivudine and seven co-infected HIV/HBV patients by Atripla^® (combination TDF, Emtricitabine and Efavirenz). Virological and biochemical responses were respectively 100% and 94% after 4 years. The rate of HBsAg seroclearance was 1.5%. Twelve of fourteen patients (85.7%) had lamivudine resistance and no cases of resistance in the TDF and Atripla^® groups. One co-infected patient developed HCC during treatment. Among patients treated by TDF, two cases of hypophosphatemia were noticed and no case of kidney failure. The treatment of CHB is certainly progressing; updated guidelines (EASL, AASLD) exist but should be adapted to the African context.

Chronic Hepatitis B, HBeAg-Negative, Nucleos(t)ide Analogues, Tenofovir, Lamivudine, Burkina Faso

Somda, K. , Sermé, A. , Coulibaly, A. , Zoungrana, S. , Compaoré, I. , Kouamou, S. , Ouattara, D. , Sombié, R. and Bougouma, A. (2016) Treatment of HBeAg-Negative Chronic Hepatitis B Patients with Nucleos(t)ide Analogues in Burkina Faso. Open Journal of Gastroenterology, 6, 387-396. doi: 10.4236/ojgas.2016.612041.